EU regulator promises speedy review of potential COVID-19 drug remdesivir

EU regulator promises speedy review of potential COVID-19 drug remdesivir

The European health regulator said on Friday its panel would conduct a speedy review of the potential COVID-19 drug, remdesivir.

The European Medicines Agency said its human medicines committee's (CHMP) timeline to assess the drug would be "reduced to the absolute minimum," adding that Gilead Sciences hadn't submitted an application for the treatment yet. (https://bit.ly/2ZPh6HA)

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.